MDUFA V: FDA And Industry Still At Odds Over Carryover Funds, Vacancies, Meeting Commitments
The most recent Medical Device User Fee Amendments meeting minutes expose how the US agency and the medtech industry continue to disagree over the agency’s previous user-fee commitments and desire to get more funding.
You may also be interested in...
The US agency’s new Office of Digital Transformation will aggregate a number of IT operations under one office to streamline the agency’s work, including its interactions with device sponsors.
In a new blogpost the US FDA acting commissioner says millions of extra dollars in President Joe Biden’s recently proposed budget would help integrate the agency’s IT systems and improve efficiencies.
Despite industry concerns the US FDA may be significantly falling behind on non-COVID-19 product reviews, analysts at Wells Fargo find that the agency has actually improved in areas such as PMA decision times.